Patents by Inventor Anne Vincent Salomon

Anne Vincent Salomon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTXR1 AS A BIOMARKER OF IMMUNOSUPPRESSIVE FIBROBLAST POPULATIONS AND ITS USE FOR PREDICTING RESPONSE TO IMMUNOTHERAPY
    Publication number: 20230258645
    Abstract: The present invention provides an in vitro method for detecting immunosuppressive fibroblasts, in particular Cancer Associated Fibroblast (CAFs) in a cancer sample from a subject suffering from cancer, wherein the method comprises detecting ANTXR1+ fibroblasts in the cancer sample from said patient. The invention also concerns an in vitro method for predicting a response of a subject suffering from cancer to an immunotherapy treatment, an immunotherapy treatment for use in the treatment of a cancer in a patient, the use of ANTXR1 as a biomarker for the identification of immunosuppressive fibroblasts, in particular immunosuppressive CAFs, an agent targeting ANTXR1+ fibroblasts for use in the treatment of a cancer in a patient, and a product or kit comprising a) an agent targeting ANTXR1+ fibroblasts and b) an immunotherapy treatment.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 17, 2023
    Inventors: FATIMA MECHTA-GRIGORIOU, YANN KIEFFER, ANNE VINCENT-SALOMON, RACHID HOCINE HOCINE
  • NEW SUBPOPULATIONS OF CANCER ASSOCIATED FIBROBLASTS AS PROGNOSIS MARKERS FOR IMMUNOTHERAPY TREATMENTS
    Publication number: 20200371105
    Abstract: The present invention provides an in vitro method for selecting a patient affected with a tumor for an immunotherapy treatment or for predicting the response of a subject affected with a tumor to an immunotherapy treatment, wherein the method comprises: (a) detecting DPP4+ CAFs (Cancer Associated Fibroblast), and/or CD73+ CAFs, and/or B7H3+ CAFs, and/or OX40L+ CAFs, and/or JAM2+ CAFs in a cancer sample from said patient; (b) determining the level(s) of DPP4+ CAFs, and/or CD73+ CAFs, and/or B7H3+ CAFs, and/or OX40L+ CAFs, and/or JAM2+ CAFs in said cancer sample, wherein the responsiveness of said patient to an immunotherapy treatment is inversely proportional to the level(s) of DPP4+ CAFs, and/or CD73+ CAFs, and/or B7H3+ CAFs, and/or OX40L+ CAFs, and/or JAM2+ CAFs in the cancer sample; (c) optionally, selecting patients with low level(s) of DPP4+ CAFs, and/or CD73+ CAFs, and/or B7H3+ CAFs, and/or OX40L+ CAFs, and/or JAM2+ CAFs as suitable for an immunotherapy treatment.
    Type: Application
    Filed: July 26, 2018
    Publication date: November 26, 2020
    Inventors: ANA COSTA, YANN KIEFFER, ANNE-MARIE GIVEL, FLORIANE PELON, ANNE VINCENT-SALOMON, FATIMA MECHTA-GRIGORIOU
  • Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer
    Publication number: 20110039789
    Abstract: The present invention relates to new methods of treatment of cancer, in particular of breast cancer, and methods of screening of compounds useful in the treatment of cancer. The present invention further provides new prognostic and/or diagnostic markers in human cancer.
    Type: Application
    Filed: August 13, 2010
    Publication date: February 17, 2011
    Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Sandrine Humbert, Frederic Saudou, John McGuire, Anne Vincent Salomon